BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2098 related articles for article (PubMed ID: 17337102)

  • 1. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
    Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
    Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus.
    Pushko P; Kort T; Nathan M; Pearce MB; Smith G; Tumpey TM
    Vaccine; 2010 Jul; 28(30):4771-6. PubMed ID: 20470801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.
    Haynes JR; Dokken L; Wiley JA; Cawthon AG; Bigger J; Harmsen AG; Richardson C
    Vaccine; 2009 Jan; 27(4):530-41. PubMed ID: 19026705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.
    Pushko P; Tumpey TM; Bu F; Knell J; Robinson R; Smith G
    Vaccine; 2005 Dec; 23(50):5751-9. PubMed ID: 16143432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC; Johansson BE
    Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes.
    Pushko P; Pearce MB; Ahmad A; Tretyakova I; Smith G; Belser JA; Tumpey TM
    Vaccine; 2011 Aug; 29(35):5911-8. PubMed ID: 21723354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.
    Crevar CJ; Ross TM
    Virol J; 2008 Oct; 5():131. PubMed ID: 18957098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.
    D'Aoust MA; Lavoie PO; Couture MM; Trépanier S; Guay JM; Dargis M; Mongrand S; Landry N; Ward BJ; Vézina LP
    Plant Biotechnol J; 2008 Dec; 6(9):930-40. PubMed ID: 19076615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge.
    Tang XC; Lu HR; Ross TM
    Viral Immunol; 2011 Aug; 24(4):311-9. PubMed ID: 21830902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.
    Saluja V; Visser MR; Ter Veer W; van Roosmalen ML; Leenhouts K; Hinrichs WL; Huckriede A; Frijlink HW
    Vaccine; 2010 Nov; 28(50):7963-9. PubMed ID: 20946860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(2):365-72. PubMed ID: 16035948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemagglutinin displayed baculovirus protects against highly pathogenic influenza.
    Tang XC; Lu HR; Ross TM
    Vaccine; 2010 Oct; 28(42):6821-31. PubMed ID: 20727393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins.
    Latham T; Galarza JM
    J Virol; 2001 Jul; 75(13):6154-65. PubMed ID: 11390617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
    Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
    Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 105.